BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines
BioVaxys Reports Positive Phase 2 Data for Maveropepimut + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab ) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S in Women with Hormone Receptor Positive/HER2 Negative Stage II-III Breast Cancer
QIMC Announces Closing of $17.3 Million Bought Deal Offering, Including Full Exercise of Underwriter's Over-Allotment Option
New Found Gold Closes Bought Deal Financing Including Full Exercise of Underwriters' Over-Allotment Option for Gross Proceeds of $115M
Couloir Capital Is Pleased to Announce That It Has Initiated Research Coverage on Pinnacle Silver and Gold
Corcel Exploration Reports Positive Results from an Induced Polarization Survey at Yuma King, Arizona
